Ranexa Dosage/Direction for Use

Patients should be given the Ranexa package leaflet and the Patient Alert Card and instructed to present their Patient Alert Card and medication list to their health care professional at each visit.
Adults: The recommended initial dose of Ranexa is 375 mg twice daily. After 2-4 weeks, the dose should be titrated to 500 mg twice daily and, according to the patient's response, further titrated to a recommended maximum dose of 750 mg twice daily.
If a patient experiences treatment-related adverse events (e.g. dizziness, nausea, or vomiting), down-titration of Ranolazine (Ranexa) to 500 mg or 375 mg twice daily may be required. If symptoms do not resolve after dose reduction, treatment should be discontinued.
Concomitant treatment with CYP3A4 and P-glycoprotein (P-gp) inhibitors: Careful dose titration is recommended in patients treated with moderate CYP3A4 inhibitors (e.g. diltiazem, fluconazole, erythromycin) or P gp inhibitors (e.g. verapamil, ciclosporin).
Concomitant administration of potent CYP3A4 inhibitors is contraindicated: Renal impairment: Careful dose titration is recommended in patients with mild to moderate renal impairment (creatinine clearance 30-80 ml/min). Ranexa is contraindicated in patients with severe renal impairment (creatinine clearance < 30 ml/min).
Hepatic impairment: Careful dose titration is recommended in patients with mild hepatic impairment. Ranolazine (Ranexa) is contraindicated in patients with moderate or severe hepatic impairment.
Elderly: Dose titration in elderly patients should be exercised with caution. Elderly may have increased ranolazine exposure due to age-related decrease in renal function. The incidence of adverse events was higher in the elderly.
Low weight: The incidence of adverse events was higher in patients with low weight (≤ 60 kg). Dose titration in patients with low weight should be exercised with caution.
Congestive heart failure (CHF): Dose titration in patients with moderate to severe CHF (NYHA Class Ill-IV) should be exercised with caution.
Paediatric population: The safety and efficacy of Ranolazine (Ranexa) in children below the age of 18 years have not been established.
No data are available.
Method of administration: Ranolazine (Ranexa) tablets should be swallowed whole and not crushed, broken, or chewed. They may be taken with or without food.